Share on StockTwits

Idera Pharmaceuticals (NASDAQ:IDRA) issued its quarterly earnings data on Tuesday. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.04, American Banking News reports.

A number of analysts have recently weighed in on IDRA shares. Analysts at TheStreet downgraded shares of Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, March 28th. On the ratings front, analysts at Zacks downgraded shares of Idera Pharmaceuticals to a “neutral” rating in a research note on Thursday, March 6th. They now have a $6.10 price target on the stock. Finally, analysts at Cowen and Company initiated coverage on shares of Idera Pharmaceuticals in a research note on Monday, March 3rd. They set an “outperform” rating on the stock.

Idera Pharmaceuticals (NASDAQ:IDRA) opened at 2.54 on Tuesday. Idera Pharmaceuticals has a 52-week low of $0.62 and a 52-week high of $6.87. The stock’s 50-day moving average is $3.35 and its 200-day moving average is $3.76. The company’s market cap is $209.2 million.

Idera Pharmaceuticals, Inc is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (NASDAQ:IDRA) – and ribonucleic acid (RNA) – based drug candidates.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.